HOUSTON -- Treatment with omalizumab (Xolair) was associated with improved endoscopic, clinical, and patient-reported outcomes in two parallel phase III studies in patients with steroid-refractory ...

The approval was supported by data from the phase 3 POLYP 1 (N=138) and POLYP 2 (N=127) trials evaluating the efficacy and safety of Xolair in adults with nasal polyps who had an inadequate response ...

Polyp recurrence occurred in more than 1 in 3 patients with chronic rhinosinusitis with nasal polyps who underwent endoscopic sinus surgery, with several prognostic factors linked with recurrence.

In the Phase 2 open-label study, REC-4881 (4 mg QD) led to a median 43% reduction (n=6 patients) in polyp burden at the Week 13 assessment at time of data cutoff. Five of six patients (83%) ...

Genentech announced positive topline data from two phase 3 trials, POLYP 1 and POLYP 2, evaluating Xolair (omalizumab) for the treatment of adults with chronic rhinosinusitis with nasal polyps (CRSwNP ...

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12) After 12 ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive topline data from two Phase III multicenter studies ...

The study was designed as a randomized controlled open trial, and was conducted at the Department of Molecular Gastroenterology and Hepatology at Kyoto Prefectural University of Medicine, Japan.

The world is experiencing a massive economic and healthcare crisis due to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) global outbreak. The rapid worldwide transmission of ...